Previous 10 | Next 10 |
Clinical hold lifted on seladelpar INDs in NASH, PBC and PSC Re-initiating clinical development focusing first on Phase 3 for PBC NEWARK, Calif., July 23, 2020 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on...
There is no guarantee that the FDA will lift the clinical hold on the development of Seladelpar. - CymaBay May 11, 2020 - 10-Q Introduction CymaBay Therapeutics ( CBAY ) is a clinical-stage biopharmaceutical company with a 3-product pipeline specializing primarily in the development of t...
CymaBay Posts Positive Seladelpar Data for Bile Duct Disorder CymaBay Therapeutics ( CBAY ) reported upbeat data for its open label Phase 2 study of seladelpar for treating patients suffering from primary biliary cholangitis. Seladelpar is a potent and selective peroxisome proliferator-a...
Fresh off positive results from a mid-stage study evaluating its lead drug in nonalcoholic steatohepatitis (NASH), French biotech Inventiva S.A. ( IVA ) has filed a preliminary prospectus for a $90M IPO. More news on: Genfit SA, CymaBay Therapeutics, Inc., Inventiva S.A., Healthcare ...
CymaBay Therapeutics ( CBAY +7.1% ) perks up, albeit on below-average volume, on the heels of new data from a previously completed open-label Phase 2 clinical trial evaluating seladelpar in patients with primary biliary cholangitis (PBC), an autoimmune disorder characterized ...
Data from previously completed open-label phase 2 study supports potential for seladelpar to improve pruritus (itching) in patients with PBC Improvements in other quality-of-life parameters also observed NEWARK, Calif., June 19, 2020 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (...
Introduction In March, I wrote an article about Genfit (NASDAQ: GNFT ) and the potential of its lead drug candidate Elafibranor in NASH. In my analysis, I underlined the huge upward potential but also underpinned the binary characteristic of the investment case. My recommendation was to ...
French biopharma Inventiva ( OTCPK:IVEVF ) has emerged as a new player in the pursuit of a treatment for nonalcoholic steatohepatitis (NASH). More news on: Inventiva S.A., Genfit SA, CymaBay Therapeutics, Inc., Healthcare stocks news, Read more ...
Shares of CymaBay Therapeutics (NASDAQ: CBAY) jumped 109% last month, according to data from S&P Global Market Intelligence . The stock popped when the company reported first-quarter 2020 operating results, which were headlined by an important update on the company's lead drug candidate...
NEWARK, Calif., June 05, 2020 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that, due to public health and safety...
News, Short Squeeze, Breakout and More Instantly...
CymaBay Therapeutics Inc. Company Name:
CBAY Stock Symbol:
NASDAQ Market:
CymaBay Therapeutics Inc. Website:
Acquisition Reinforces Gilead’s Leadership in Developing Innovative Therapies For Challenging Liver Diseases Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction to acquire CymaBay Therapeutics, Inc. (Nasdaq: CBAY) for appr...
CymaBay Therapeutics, Inc. (NASDAQ: CBAY) is the focus of IBN's latest stock spotlight. The company's shares have moved 0.06% on the day to $32.49. CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chr...
2024-03-12 10:45:01 ET UiPath Inc (PATH) PATH is trading UP for the last 5 days, and it at trading at $24.64 with volume of 4,269,666 and a one day change of $0.54 (2.25%). UiPath Inc has a 52-week low of 12.38 and a 52-week high of $27.87. The business's 50-day moving average price...